MedTrace Logo

The Effect of Increasing Dialysate Magnesium on Calcification Propensity in Subjects on Haemodialysis

NCT02977117 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2018-06-06

No results posted yet for this study

Summary

The purpose of this trial is to examine the effect of increasing dialyse magnesium on serum calcification propensity in subjects with end-stage renal disease treated with haemodialysis.

Conditions

  • Endstage Renal Disease

Interventions

OTHER

Dialysate magnesium (1.0 mmol/L)

Dialysate magnesium will be increased from 0.5 mmol/L to 1.0 mmol/L for 4 weeks after which subjects will return to dialysate magnesium 0.5 mmol/L for 2 weeks observation.

OTHER

Dialysate magnesium (0.5 mmol/L)

Dialysate magnesium will be maintained at 0.5 mmol/L for the duration of the trial.

Sponsors & Collaborators

  • Iain Bressendorff

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02977117 on ClinicalTrials.gov